Reports of pulmonary aspiration and difficulties in diagnosing gastrointestinal complications in the perioperative period have highlighted the need for clear clinical guidance to manage these patients ...
The use of GLP-1s is linked to improved inflammatory bowel disease outcomes in patients with concomitant inflammatory bowel ...
Addiction is yet another area where GLP-1s might be effective. Preliminary evidence looks promising, but questions remain.
Glucagon-like peptide-1 (GLP-1) brands Wegovy and Zepbound, along with their counterparts approved for type 2 diabetes — Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, respectively — have begun to ...
Berberine, green tea extract and taurine are just some of the ingredients advertised as being able to ‘boost’ GLP-1 levels.
There’s no single GLP-1 diet plan you need to follow. If you’re taking — or thinking about taking — a GLP-1 medication like ...
Obese people ‘will have to wait’ for Mounjaro amid carefully managed NHS rollout - The decision will help ‘protect other ...
Viking Therapeutics shows strong data with VK2735, a potential competitor to major drugs. Discover why VKTX stock is a ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. The ...
A study finds that anti-obesity medications may help reduce alcohol consumption, with nearly half of participants in weight ...
Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.